Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Clinical trial NCT05633654 · RECRUITING
Trial details
- NCT number
- NCT05633654
- Sponsor
- Gilead Sciences
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-12
- Primary completion
- 2027-06-01
- Enrollment
- 1514
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.